# US 2013/0296575 A1 · Sunitinib and salts thereof and their polymorphs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296575 A1
- Document ID: US20130296575A1
- Status: Published application
- Kind: A1
- Application number: 13/944,699
- Filed: 2013-07-17
- Published: 2013-11-07
- Earliest claimed: 2008-07-24
- Assignees: Teva Pharmaceutical Industries Ltd.
- Applicants: Teva Pharmaceutical Industires Ltd.
- Inventors: Alexandr JEGOROV; Ales Gavenda; Pavel Vraspir; Augusto Canavesi; Francesca Scarpitta
- Web page: https://patentgrep.com/patent/US20130296575A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

Sunitinib acetate.

### Claim 7 (depends on 6)

The Sunitinib acetate of claim 6, wherein the sunitinib acetate is in isolated form.

### Claim 8 (depends on 6)

The Sunitinib acetate of claim 6, wherein the Sunitinib acetate is in solid form.

### Claim 9 (depends on 6)

The Sunitinib acetate of claim 6, wherein the sunitinib acetate is in crystalline form.

### Claim 10

A crystalline form of Sunitinib acetate characterized by data selected from a group consisting of a PXRD pattern having peaks at about 5.1, 9.6, 10.2, 12.8 and 16.9±0.2 degrees 2-theta, a PXRD pattern as depicted in FIG. 12, a solid-state 13C NMR spectrum having signals at about 165.2, 134.5, 130.4, 118.7, 115.7, 112.5 and 110.9±0.2 ppm, a solid-state 13C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of about 63.6, 32.9, 28.8, 17.1, 14.1, 10.8 and 9.2±0.1 ppm, a solid-state —C NMR spectrum depicted in FIG. 20 and combinations thereof.

### Claim 11 (depends on 10)

The crystalline form of Sunitinib acetate of claim 10, further characterized by data selected from a group consisting of: a PXRD pattern having peaks at about 17.4, 17.7, 23.1, 26.0 and 27.0±0.2 degrees 2-theta, a DSC thermogram as depicted in FIG. 13 and a TGA thermogram as depicted in FIG. 14.

### Claim 12 (depends on 10)

The crystalline form of Sunitinib acetate of claim 10, wherein the crystalline form is an acetic acid solvate.

### Claim 13

A crystalline form of Sunitinib acetate characterized by data selected from a group consisting of: a PXRD pattern having peaks at about 6.1, 11.0, 15.8, 16.4 and 20.2±0.2 degrees 2-theta, a PXRD pattern as depicted in FIG. 17, a solid-state 13 C NMR spectrum having signals at about 166.1, 133.0, 119.0, 114.5, 109.9 and 108.6±0.2 ppm, a solid-state 13C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of about 65.0, 31.9, 17.9, 13.4, 8.8 and 7.5±0.1 ppm, a solid-state 13C NMR spectrum depicted in FIG. 21 and combinations thereof.

### Claim 14 (depends on 13)

The crystalline form of Sunitinib acetate of claim 13, further characterized by data selected from a group consisting of: a PXRD pattern having peaks at about 9.1, 18.2, 24.4, 25.0 and 29.3±0.2 degrees 2-theta, a DSC thermogram as depicted in FIG. 18, and a TGA thermogram as depicted in FIG. 19.

### Claim 15 (depends on 13)

The crystalline form of Sunitinib acetate of claim 13, wherein the crystalline form is anhydrous.

### Claim at position 12

16-27. (canceled)

### Claim 28 (depends on 10)

A process for preparing Sunitinib malate comprising converting the crystalline Sunitinib acetate of claim 10 to Sunitinib malate.

### Claim 29 (depends on 13)

A process for preparing Sunitinib malate comprising converting the crystalline Sunitinib acetate of claim 13 to Sunitinib malate.

### Claim 30 (depends on 28)

A process of claim 28, wherein Sunitinib malate is characterized by diffraction peaks at about 13.2 and 24.2 degrees two-theta.

### Claim 31 (depends on 29)

A process of claim 29, wherein Sunitinib malate is characterized by diffraction peaks at about 13.2 and 24.2 degrees two-theta.
